FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4324137007> ?p ?o ?g. }

• W4324137007 endingPage "TPS292" @default.
• W4324137007 startingPage "TPS292" @default.
• W4324137007 abstract "TPS292 Background: PT-112 is a novel small I-O molecule currently in development for several cancers. Preclinical studies have shown the robust induction of immunogenic cell death by PT-112, leading to an anti-cancer adaptive immune response. Biodistribution experiments in mice showed PT-112’s partial bone affinity. In two prior phase I studies, late-line metastatic castration-resistant prostate cancer patients (mCRPC pts) were treated with evidence of anti-cancer activity, including tumor volume reductions, improvements in PET and bone scans, PSA and alkaline phosphatase (ALP) reductions, and anecdotal cases of improvement in disease-related pain. This, taken together with the immunogenic and osteotropic properties observed in preclinical work, provided a strong rationale to further explore PT-112 in mCRPC, an immunologically “cold” disease with a high prevalence of bone metastases. Moreover, in an analysis of >6,000 mCRPC pts, circulating tumor cell (CTC) declines (CTC0 and CTC conversions) were correlated with improvements in survival to a greater extent than PSA declines (PSA 50 ) (Heller et al., JCO, 36:6 2017), prompting incorporation of CTC changes as a secondary endpoint. Methods: The primary objective of the study is to define the dose regimen of PT-112 for pivotal study. Pts are randomized to one of three arms, receiving IV PT-112 on 28-day cycles via one hour infusions on (1) Days 1 and 15 at 250 mg/m 2 , (2) Days 1 and 15 at 360 mg/m 2 , or (3) Days 1 and 15 of cycle 1 at 360 mg/m 2 followed by 250 mg/m 2 on Day 15 of subsequent cycles. Key eligibility criteria include radiographically progressive disease at study entry; ≥3 life-prolonging therapies for metastatic disease including 1-2 taxanes, ≥1 new generation anti-androgen therapies, and other drugs FDA approved on the basis of survival; and allowing bone-only metastatic disease. Efficacy assessments comprise disease control rate at 4 months (DCR4) using RECIST and PCWG3 criteria, objective response rate, CTC0 and CTC conversion, PSA 50 and ALP reductions. Additionally, T cell receptor sequencing is conducted to characterize treatment-induced changes in T cell fraction and clonal expansions, as a means of generating meaningful supportive data on the immune mechanism of PT-112 monotherapy. A Fleming two-stage design will be used to assess each arm, with a 20% DCR4 as the null hypotheses, requiring ≥6 of 25 pts responding in stage one and ≥14 of 45 in total to reject the null. In addition, other efficacy measures, such as CTC responses, as well as exposure/response and exposure/safety analyses will be applied to characterize the risk/benefit ratio and select the optimal dose regimen for PT-112. As of October 11 th , 2022, 38 pts have been enrolled out of a planned maximum of 135. Clinical trial information: NCT02266745 ." @default.
• W4324137007 created "2023-03-15" @default.
• W4324137007 creator A5002358672 @default.
• W4324137007 creator A5007663088 @default.
• W4324137007 creator A5008786567 @default.
• W4324137007 creator A5015581478 @default.
• W4324137007 creator A5030233600 @default.
• W4324137007 creator A5030769953 @default.
• W4324137007 creator A5042373345 @default.
• W4324137007 creator A5053079426 @default.
• W4324137007 creator A5064024896 @default.
• W4324137007 creator A5072850546 @default.
• W4324137007 creator A5076162736 @default.
• W4324137007 creator A5084413226 @default.
• W4324137007 creator A5091696839 @default.
• W4324137007 date "2023-02-20" @default.
• W4324137007 modified "2023-10-14" @default.
• W4324137007 title "A phase 2 study of immunogenic cell death inducer PT-112 in patients with metastatic castration-resistant prostate cancer." @default.
• W4324137007 doi "https://doi.org/10.1200/jco.2023.41.6_suppl.tps292" @default.
• W4324137007 hasPublicationYear "2023" @default.
• W4324137007 type Work @default.
• W4324137007 citedByCount "0" @default.
• W4324137007 crossrefType "journal-article" @default.
• W4324137007 hasAuthorship W4324137007A5002358672 @default.
• W4324137007 hasAuthorship W4324137007A5007663088 @default.
• W4324137007 hasAuthorship W4324137007A5008786567 @default.
• W4324137007 hasAuthorship W4324137007A5015581478 @default.
• W4324137007 hasAuthorship W4324137007A5030233600 @default.
• W4324137007 hasAuthorship W4324137007A5030769953 @default.
• W4324137007 hasAuthorship W4324137007A5042373345 @default.
• W4324137007 hasAuthorship W4324137007A5053079426 @default.
• W4324137007 hasAuthorship W4324137007A5064024896 @default.
• W4324137007 hasAuthorship W4324137007A5072850546 @default.
• W4324137007 hasAuthorship W4324137007A5076162736 @default.
• W4324137007 hasAuthorship W4324137007A5084413226 @default.
• W4324137007 hasAuthorship W4324137007A5091696839 @default.
• W4324137007 hasConcept C121608353 @default.
• W4324137007 hasConcept C126322002 @default.
• W4324137007 hasConcept C126894567 @default.
• W4324137007 hasConcept C143998085 @default.
• W4324137007 hasConcept C203014093 @default.
• W4324137007 hasConcept C203092338 @default.
• W4324137007 hasConcept C2776139714 @default.
• W4324137007 hasConcept C2779013556 @default.
• W4324137007 hasConcept C2780192828 @default.
• W4324137007 hasConcept C2781190966 @default.
• W4324137007 hasConcept C2781413609 @default.
• W4324137007 hasConcept C535046627 @default.
• W4324137007 hasConcept C61238886 @default.
• W4324137007 hasConcept C71924100 @default.
• W4324137007 hasConcept C8891405 @default.
• W4324137007 hasConceptScore W4324137007C121608353 @default.
• W4324137007 hasConceptScore W4324137007C126322002 @default.
• W4324137007 hasConceptScore W4324137007C126894567 @default.
• W4324137007 hasConceptScore W4324137007C143998085 @default.
• W4324137007 hasConceptScore W4324137007C203014093 @default.
• W4324137007 hasConceptScore W4324137007C203092338 @default.
• W4324137007 hasConceptScore W4324137007C2776139714 @default.
• W4324137007 hasConceptScore W4324137007C2779013556 @default.
• W4324137007 hasConceptScore W4324137007C2780192828 @default.
• W4324137007 hasConceptScore W4324137007C2781190966 @default.
• W4324137007 hasConceptScore W4324137007C2781413609 @default.
• W4324137007 hasConceptScore W4324137007C535046627 @default.
• W4324137007 hasConceptScore W4324137007C61238886 @default.
• W4324137007 hasConceptScore W4324137007C71924100 @default.
• W4324137007 hasConceptScore W4324137007C8891405 @default.
• W4324137007 hasIssue "6_suppl" @default.
• W4324137007 hasLocation W43241370071 @default.
• W4324137007 hasOpenAccess W4324137007 @default.
• W4324137007 hasPrimaryLocation W43241370071 @default.
• W4324137007 hasRelatedWork W1898921923 @default.
• W4324137007 hasRelatedWork W1966736945 @default.
• W4324137007 hasRelatedWork W2010765098 @default.
• W4324137007 hasRelatedWork W2060708716 @default.
• W4324137007 hasRelatedWork W2094570582 @default.
• W4324137007 hasRelatedWork W2588988563 @default.
• W4324137007 hasRelatedWork W2735900144 @default.
• W4324137007 hasRelatedWork W3157765547 @default.
• W4324137007 hasRelatedWork W3160004952 @default.
• W4324137007 hasRelatedWork W4226303148 @default.
• W4324137007 hasVolume "41" @default.
• W4324137007 isParatext "false" @default.
• W4324137007 isRetracted "false" @default.
• W4324137007 workType "article" @default.